INTRODUCTION
============

Annually, 5--10% of patients with systemic cancer will develop symptomatic spine metastases ([@B16]). Patients with common malignancies such as breast, prostate, and lung cancer develop spine metastases at higher rates. The management of vertebral body (VB) metastases varies depending on an individual's prognosis and the involved spine's structural integrity. Patients carrying a poor prognosis without evidence of bony retropulsion into the anterior epidural space or spinal instability have traditionally received conventional radiation therapy alone with moderate success ([@B3]). Despite providing excellent early palliation of symptoms, conventional radiation has resulted in poor local control rates with one major survey placing the crude, overall local control rate at 77%, and another large Phase III study estimating a median time to recurrence of 5 months ([@B12]; [@B13]). Patients remain at significant risk of developing debilitating spine progression following conventional irradiation ([@B17]; [@B9]).

In an effort to enhance local control and minimize radiation toxicity researchers in the past decade have explored various means of improving spine irradiation. This research has resulted in a new treatment paradigm, stereotactic body radiation therapy (SBRT). With improved dose distributions and accuracy, SBRT has facilitated the safe painless delivery of high doses of radiation quickly to localized spine tumors. Multiple studies have confirmed the efficacy of SBRT with early symptomatic improvement seen in 86--96% of treated patients following delivery of one to five fractions ([@B7],[@B5]; [@B19],[@B18]; [@B2]; [@B21],[@B20]; [@B1]; [@B8]; [@B4]). Despite growing evidence supporting SBRT in poor prognosis, previously irradiated spine metastases patients, few studies have established local control rates for newly diagnosed relatively good prognosis patients with single VB metastases.

The CyberKnife^®^ System (Accuray Incorporated, Sunnyvale, CA, USA) has been successfully employed at Georgetown University Hospital since early 2002 to treat spine tumors with fiducial tracking. Institutional reports have documented this technology's ability to reliably palliate tumor induced spine pain with potentially safer fractionated radiation doses ([@B2]; [@B4]). The accuracy and flexibility of the fiducial-free system, X-sight spine tracking, prompted us in late 2005 to evaluate a five-fraction CyberKnife SBRT treatment for good prognosis patients with single VB metastases that were not previously irradiated ([@B14]; [@B10]). The system's unique configuration facilitates the accurate delivery of fractionated high dose radiation, despite the close proximity of such tumors to radiation sensitive structures such as the spinal cord and esophagus ([@B11]). We report outcomes for 20 consecutively treated, eligible patients with newly diagnosed single VB metastases treated using this novel treatment approach.

MATERIALS AND METHODS {#s1}
=====================

ELIGIBILITY
-----------

This retrospective analysis of an established departmental treatment approach was approved by the MedStar Health Research Institute -- Georgetown University Oncology Institutional Review Board. Consecutive patients with good prognosis single VB metastases treated with five-fraction fiducial-free CyberKnife SBRT between September 2005 and September 2010 were analyzed. Patients were considered to have a good prognosis if they had a favorable performance status (ECOG 0--1) and oligometastatic disease. A tumor was considered a single VB metastasis if it primarily involved a single VB. Patients with previously irradiated spine or uncorrected spinal cord compression were excluded from analysis.

TREATMENT PLANNING AND DELIVERY
-------------------------------

A fine-cut (1.25 mm) contrast enhanced treatment planning CT scan was obtained in the supine treatment position for each patient. Oral contrast was routinely used to delineate the esophagus. CT myelogram was used to define the spinal cord when clinically indicated. The planning target volume (PTV), either the gross tumor volume (GTV), or the involved VB, was contoured at the discretion of the treating physician. A treatment plan was generated using the MultiPlan 5.2.1 non-isocentric, inverse-planning algorithm with tissue density heterogeneity corrections for lung based on an effective depth correction. The radiation dose was divided into five equal fractions of 6--7 Gy, prescribed to an isodose line that covered at least 80% of the PTV. Guidelines for dose limits to critical structures are provided in **Table [1](#T1){ref-type="table"}**. Patients were treated in the supine position as previously described using fiducial-free CyberKnife spine tracking ([@B14]; [@B10]).

###### 

Institutional maximum point dose limit guidelines for adjacent critical structures.

  Adjacent critical structure   Maximum point dose limit
  ----------------------------- --------------------------
  Spinal cord                   30
  Nerve roots                   35
  Esophagus                     40
  Bowel                         40

FOLLOW-UP
---------

Patients were followed with physical examination plus MRI and/or PET/CT imaging at 3- to 6-month intervals per routine institutional practice. Local tumor recurrence was defined as progression of the treated tumor per selected imaging. Biopsies were obtained when clinically indicated. Toxicities were scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 ([@B15]).

STATISTICAL ANALYSIS
--------------------

Statistical analysis was performed with the SPSS 17 (IBM Corporation, Armonk, NY, USA) statistical software package. The follow-up duration was defined as the time from the date of treatment completion to the last date of follow-up or the date of death. Actuarial local control and overall survival were calculated using the Kaplan--Meier method. For the sake of robustness, all reported ranges are interquartile (IQR, Q~1~--Q~3~).

RESULTS
=======

PATIENT CHARACTERISTICS
-----------------------

Twenty consecutive patients, 6 men and 14 women, were treated over a 60-month period and followed for a minimum of 12 months or until death (**Table [2](#T2){ref-type="table"}**). Primary cancers included sarcoma (*n* = 7), breast cancer (*n* = 5), non-small cell lung cancer (*n* = 2), prostate cancer (*n* = 1), clear cell renal cancer (*n* = 1), papillary thyroid cancer (*n* = 1), melanoma (*n* = 1), plasmacytoma (*n* = 1), and acinic cell salivary gland cancer (*n* = 1). All patients were chemotherapy candidates; 30% required corpectomy prior to CyberKnife treatment.

###### 

Treatment characteristics.

  Patient   Histology                    Level   Surgery   PTV (cc)   Prescription dose (Gy)   Target
  --------- ---------------------------- ------- --------- ---------- ------------------------ --------
  1         Sarcoma (MFH)                T5      Y         51         35                       VB
  2         Breast                       L4      N         89         30                       VB
  3         Sarcoma (leiomyosarcoma)     S2      Y         181        35                       GTV
  4         Breast                       T9      N         42         30                       VB
  5         Breast                       T7      N         19         30                       VB
  6         Lung (NSCLC)                 T9      N         91         30                       GTV
  7         Thyroid                      T10     N         23         35                       GTV
  8         Prostate                     T12     N         99         35                       VB
  9         Sarcoma (liposarcoma)        L1      N         12         35                       GTV
  10        Melanoma                     L4      Y         292        30                       VB
  11        Sarcoma (leiomyosarcoma)     L3      Y         150        35                       VB
  12        Sarcoma (osteosarcoma)       C6      N         13         35                       VB
  13        Renal                        T8      N         3          30                       VB
  14        Plasmacytoma                 T7      N         20         30                       GTV
  15        Breast                       L1      N         81         30                       VB
  16        Breast                       L1      N         114        30                       VB
  17        Sarcoma (rhabdomyosarcoma)   T11     Y         350        30                       GTV
  18        Salivary gland (acinic)      S3      N         324        35                       GTV
  19        Lung (NSCLC)                 T2      N         336        30                       GTV
  20        Sarcoma (giant cell)         T1      Y         124        35                       VB

GTV, gross tumor volume; NSCLC, non-small cell lung cancer; MFH, malignant fibrous histiocytoma; VB, vertebral body

.

TREATMENT CHARACTERISTICS
-------------------------

Treatment plans were composed of hundreds of pencil beams delivered using a single 10--35 mm diameter collimator (median, 20 mm). The majority of patients (60%) received VB irradiation; the remainder had the GTV alone targeted. The mean PTV was 121 cc (SD, 116 cc). Radiation was delivered in five equal fractions of 6--7 Gy over a median of 7 days (IQR, 5--9 days). The median prescription isodose line was 70% (IQR, 65--77%), the median dose was 30 Gy (IQR, 30--35 Gy) and the median PTV coverage was 95% (IQR, 87--97%). The resulting mean maximum point doses delivered to the spinal cord and esophagus were 26.4 Gy (SD, 5.1 Gy) and 29.1 Gy (SD, 8.9 Gy), respectively.

LOCAL CONTROL AND SURVIVAL
--------------------------

Local control and survival outcomes were favorable (**Figure [1](#F1){ref-type="fig"}**; **Table [3](#T3){ref-type="table"}**). At a median follow-up of 34 months for surviving patients, the 1- and 2-year Kaplan--Meier local control estimates were 80 and 73%, respectively (**Figure [2](#F2){ref-type="fig"}**). Of the five observed local failures, two were infield local failures in patients who had received irradiation to the GTV alone and three were paravertebral failures just outside the PTV in patients requiring corpectomy prior to treatment. Four of the seven treated sarcomas failed locally. No local failures were identified beyond 14 months or in patients who completed VB irradiation alone. The 1- and 2-year Kaplan--Meier overall survival estimates were relatively favorable at 80 and 57%, respectively (**Figure [3](#F3){ref-type="fig"}**). Nine deaths were attributed to metastatic disease; one death was attributed to local recurrence (**Figure [4](#F4){ref-type="fig"}**).

![Osteosarcoma C6 oligometastasis PET/CT scan with a tumor SUV~max~ of 11 **(A)**; **(B)** CyberKnife treatment plan showing the vertebral body planning treatment volume in yellow and the 35 Gy isodose line in blue; and **(C)** PET/CT scan at 3 years post-treatment shows a durable complete response with a tumor SUV~max~ of 1.7.](fonc-02-00039-g001){#F1}

###### 

Clinical outcomes.

  Patient   Local failure (month)   Vital status   Survival (month)   Cause of death
  --------- ----------------------- -------------- ------------------ ----------------
  1         7                       Dead           36                 Metastases
  2         \-                      Dead           27                 Metastases
  3         \-                      Dead           20                 Metastases
  4         \-                      Dead           18                 Metastases
  5         \-                      Dead           12                 Metastases
  6         5                       Dead           12                 Metastases
  7         \-                      Alive          63                 \-
  8         \-                      Alive          50                 \-
  9         14                      Dead           24                 Local failure
  10        \-                      Alive          40                 \-
  11        12                      Alive          40                 \-
  12        \-                      Alive          39                 \-
  13        \-                      Dead           14                 Metastases
  14        \-                      Alive          28                 \-
  15        \-                      Alive          25                 \-
  16        \-                      Alive          25                 \-
  17        6                       Dead           10                 Metastases
  18        \-                      Alive          14                 \-
  19        \-                      Dead           6                  Metastases
  20        \-                      Alive          12                 \-

![**Kaplan--Meier plot of local control**.](fonc-02-00039-g002){#F2}

![**Kaplan--Meier plot of overall survival**.](fonc-02-00039-g003){#F3}

![**(A)** Solitary L1 liposarcoma metastasis; **(B)** CyberKnife treatment plan dose distribution with gross tumor volume shown in red and the 35 Gy isodose line in blue; and **(C)** MRI at 14 months post-treatment with local recurrence.](fonc-02-00039-g004){#F4}

COMPLICATIONS
-------------

Conservative maximum point dose guidelines for normal tissues were generally observed. Patients receiving maximum esophageal point doses greater than 35 Gy (*n* = 4) experienced acute dysphagia/esophagitis (Grade I/II) lasting several weeks. No skin, musculoskeletal or neurologic toxicities were attributed to CyberKnife treatment.

DISCUSSION
==========

The CyberKnife's image guidance system uniquely facilitates both extreme accuracy (\<1 mm) and fractionation ([@B11]). In our opinion, both capabilities are necessary to optimally treat tumors in close proximity to the spinal cord. Georgetown University Hospital researchers have documented the CyberKnife's ability to reliably palliate tumor induced spine pain with potentially safer fractionated radiation doses using fiducial tracking ([@B2]; [@B4]). However, the required fiducial placement uniformly necessitated a delay in treatment and was a potentially hazardous invasive procedure that concerned potential users. In 2005 the CyberKnife image guidance system was reconfigured to track the spine itself ([@B14]; [@B10]). This development led to the broad adoption of CyberKnife spine SBRT.

With the introduction of fiducial-free CyberKnife spine technology to Georgetown University Hospital in 2005, we instituted a five-fraction treatment approach for newly diagnosed single VB oligometastases. This fractionation schedule was selected to optimize local control and normal tissue radiation tolerance in this group of patients with expected favorable survival. Twenty patients were treated in 60 months and followed for a minimum of 1 year. At a median follow-up of 34 months for surviving patients, the 1- and 2-year Kaplan--Meier local control estimates are 80 and 73%, respectively. This is somewhat lower than the typical 90% local control rates reported by prior institutional series ([@B6]). Although this small decrement in local control is likely the result of the improved survival seen in this cohort, several minor adjustments to our approach have been made in an effort to improve this outcome.

Prior to proceeding with our five-fraction fiducial-free CyberKnife approach for single VB metastases there was no standard PTV for spine SBRT. Therefore, we left it to the treating physician to determine whether they would target the GTV or the VB itself. The majority of physicians (60%) chose to treat the VB in order to address microscopic disease spread within the VB itself. Two local failures in this study were attributed to irradiation of only the GTV; future patients will receive VB irradiation only.

The remaining three local failures were paravertebral failures just outside the PTV in patients with advanced spine metastases requiring corpectomy. The local failure rate for postoperative patients in this study was 50%. Therefore, we have decided to exclude such patients from this approach in the future; it is our opinion that good prognosis patients with likely intraoperative microscopic disease spread would be better treated with a combination of conventional radiation and CyberKnife as a boost.

Finally, it is likely that good prognosis patients with single VB metastases would benefit from dose escalation ([@B20]). The five local failures observed in this study were seen in patients with tumors that were generally considered radioresistant (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}; [@B6]). Furthermore, meaningful toxicity was observed only in patients receiving maximum esophagus point doses greater than 35 Gy. A planned institutional dose escalation study will gradually raise the current typically dose limiting maximum spinal cord point dose from 30 to 35 Gy as tolerated. The current esophagus maximum point dose will be decreased to 35 Gy to minimize acute dysphagia.

CONCLUSION
==========

Five-fraction fiducial-free CyberKnife SBRT is a promising treatment option for VB tumors, demonstrating encouraging local control rates with nominal toxicity despite the close proximity of such tumors to the spinal cord and esophagus. A prospective dose escalation study targeting the intact VB is planned to further enhance local control in this patient population.
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